Preclinically, PT630 (GluBoroPro dipeptide), a pharmacological inhibitor of FAP, has been well demonstrated to cause a drastically reduced infiltration of myofibroblasts into tumor tissues, resulting in diminished tumor growth [74]. The gene discussed is FAP; the disease is neoplasm.